Denise Neves Gameiro, Author at Labiotech.eu

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

genzyme sanofi enzyme replacement therapy pompe disease neogaa neo1

News and Trends 8 Mar 2016

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

Sanofi Genzyme (Boston and France) have obtained good phase I/II results with a candidate for the rare Pompe Disease and expects to move to phase III in the second quarter of 2016. Sanofi Genzyme continues to bet on rare diseases and neurodegenerative disorders, now with a therapy for late-onset Pompe Disease. Pompe Disease is a […]

March 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

karolinska development akinion acute myeloid leukemia aml liver toxicity phase II akn 028 tyrosine kinase inhibitor

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M hit in its portfolio valuation. Sad news for Akinion. This Stockholm-based drug developer decided to halt the development of its lead candidate, APN-028. This happens after […]

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

crispr mimivire aix nature virus synbio biotech

News and Trends 4 Mar 2016

This Megavirus has its own CRISPR-like Defense System

MIMIVIRE is the name French researchers have given to the immunity mechanism of mimivirus, and that they have now described in a new paper for Nature. What is a mimivirus? What is viral immunity? What is life? What is CRISPR? Well, for the last question, you should read our review on CRISPR. As for the rest, […]

March 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

horizon centarui axxinity venture therapeutics alphamers cancer1

News and Trends 4 Mar 2016

The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

Merck (Germany) has initiated a phase III trial for a biosimilar of AbbVie’s Humira, to treat Chronic plaque psoriasis. This is a big deal as Humira is the best selling biologics of all time (over €10Bn in annual revenues). Merck is developing a candidate (MSB11022) as a biosimilar of adalimumab, a human monoclonal antibody sold under the brand Humira – a key […]

March 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

rheumatoid arthritis sirukumab galapagos johnson johnson JJ abbvie

News and Trends 3 Mar 2016

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

J&J has sold over 2 million of Galapagos‘ shares, which had been inherited from previous acquisitions, reducing its equity in this Belgian Biotech to below 5%. What’s wrong? Back in May, we talked about how J&J and AbbVie could be entering a fight for Galapagos’ filgotinib, a drug for rheumatoid arthritis (RA) that performed well […]

March 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

redhill biopharma israel gastrointestinal crohns cancer pancreatic rhb 104

News and Trends 3 Mar 2016

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

RedHill Biopharma (Israel) is in a solid financial position to reap the benefits of several advanced trials in inflammatory gastrointestinal diseases, including Crohn’s. The company just released its financial statements, with some interesting highlights… Based in Tel-Aviv, RedHill is developing small molecule oral drugs for a variety of conditions connected to the gastrointestinal tract. It is listed […]

March 3, 2016 - 3 minutesmins - By Denise Neves Gameiro

leukemia mesothelioma myeloma sellas cancer immunoncology fda wt1

News and Trends 2 Mar 2016

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

Sellas (Switzerland) is developing an immunotherapeutic cancer vaccine – which can be easier now that the FDA granted it Orphan Drug designations for two types of cancer (for the lung area and a type of leukemia). Sellas is a biopharma developing treatments for different cancers and diseases of the central nervous system (CNS). Its lead […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

win horizon centauri antibody avvinity cancer alphamer

News and Trends 2 Mar 2016

New Joint Venture to Shake Up Immuno-Oncology in the UK

Avvinity Therapeutics is the new child of two UK Biotechs: Horizon Discovery and Centauri. The goal? To create the ultimate immuno-oncology toolbox with€32M. Just created, Avvinity is a joint venture targeting the immuno-oncology field, which is worth around €32M – and is only expected to grow. The biotechnological approach to cancer treatments has many Pharma and Biotech companies interested, […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Mar 2016

Artificial Hearts are one Step Closer to the Market with €50M in Funding

Carmat (France) has raised €50M from private investors (dwarfing its 2015’s €3M reserves) in order to further develop its artificial hearts during 2016 and apply for CE Marking. This French Medtech company is developing an artificial heart (one of top examples of futuristic cyborg-like technologies in biotech) that could help patients with end-stage biventricular heart failure. There are people […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

exelixis ipsen cancercabozantinib renal liver endometrial nsclc

News and Trends 1 Mar 2016

French Ipsen closes €700M deal for Californian Cancer Drug

Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights for a multi-organ cancer candidate outside US, Canada and Japan. California-based Exelixis has found an European partner to license the small molecule drug, cabozantinib. Ipsen, a French biotech group, will have comercialization rights for cabozantinib worldwide, except in the US and […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 29 Feb 2016

Our Top 5 Articles on Biotech & Rare Disease

Today is Rare Disease Day 2016. Because it is an important field for Biotech, we went back to review some of our best articles on the topic from the Labiotech archives. Here are some of our best – in addition to an overview of 7 Rare diseases and who in Biotech is working on them. Nº […]

February 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 29 Feb 2016

Exploiting the Power of NGS to Diagnose Rare Diseases

Diploid (Belgium) is using genome sequencing data to diagnose rare diseases – and is now charging only if its algorithms can match the genome to a specific rare disease. Patients of rare diseases often struggle with the lack of therapies options – an empty space where Biotechs seem to thrive. But therapy availability is not the […]

February 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Denise Neves Gameiro

About

Articles by Denise Neves Gameiro

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

Swedish Investment loses €8M over failed Phase I/II for Leukemia

This Megavirus has its own CRISPR-like Defense System

The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

New Joint Venture to Shake Up Immuno-Oncology in the UK

Artificial Hearts are one Step Closer to the Market with €50M in Funding

French Ipsen closes €700M deal for Californian Cancer Drug

Our Top 5 Articles on Biotech & Rare Disease

Exploiting the Power of NGS to Diagnose Rare Diseases

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Denise Neves Gameiro

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!